T C. Barnett-Tapia

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications

Professor Vera Bril (1948-2026): Scientist, Mentor, and Close Friend to the Canadian Diabetes Community.

Professor Vera Bril (1948-2026): Scientist, Mentor, and Close Friend to the Canadian Diabetes Community.

Journal: Canadian journal of diabetes
Published: August 06, 2026

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Journal: Neurology. Clinical practice
Published: July 09, 2026

Understanding patients' experiences and needs around decision-making for bulbar symptom management at a multidisciplinary ALS clinic.

Understanding patients' experiences and needs around decision-making for bulbar symptom management at a multidisciplinary ALS clinic.

Journal: Disability and rehabilitation
Published: July 01, 2026

Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting.

Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting.

Journal: Frontiers in neurology
Published: May 16, 2026

Unilateral Lisch Nodules without Neurofibromatosis 1: A Finding to Observe or Worry About?

Unilateral Lisch Nodules without Neurofibromatosis 1: A Finding to Observe or Worry About?

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Published: May 08, 2026

The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps.

The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps.

Journal: Neurology
Published: April 09, 2026

Myasthenia gravis in Latin America and the Caribbean: epidemiology, resources, and accessibility to diagnosis and treatment.

Myasthenia gravis in Latin America and the Caribbean: epidemiology, resources, and accessibility to diagnosis and treatment.

Journal: Frontiers in public health
Published: January 19, 2026

Effect of the COVID-19 pandemic on initiations of opioid agonist therapy in Ontario: A population-based interrupted time series analysis.

Effect of the COVID-19 pandemic on initiations of opioid agonist therapy in Ontario: A population-based interrupted time series analysis.

Journal: The International journal on drug policy
Published: January 17, 2026

Ask and you will find: the importance of measuring stigma due to cutaneous neurofibromas in neurofibromatosis type 1.

Ask and you will find: the importance of measuring stigma due to cutaneous neurofibromas in neurofibromatosis type 1.

Journal: The British journal of dermatology
Published: December 21, 2025

Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG-REST): Estimating the Clinical and Economic Burden in Ontario, Canada.

Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG-REST): Estimating the Clinical and Economic Burden in Ontario, Canada.

Journal: European journal of neurology
Published: November 07, 2025

Identifying Neurodevelopmental Domain Subgroups in Autism and ADHD.

Identifying Neurodevelopmental Domain Subgroups in Autism and ADHD.

Journal: Journal of autism and developmental disorders
Published: November 05, 2025

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.

Journal: Nature medicine
Published: October 27, 2025
Showing 1-12 of 56

Last Updated: 09/26/2026